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Abstract 
Flagellin is a protein-based adjuvant that activates toll-like receptor (TLR) 5. Flagellin has been 
actively explored as vaccine adjuvants and carriers. Preclinical and clinical studies find flagellin-
based vaccines have a risk to induce systemic adverse reactions potentially due to its overt 
activation of TLR5. To improve safety and immunogenicity of flagellin as vaccine carriers, FljB 
was displayed at high densities on hepatitis b core (HBc) virus-like particle (VLP) surface upon 
c/e1 loop insertion. FljB-HBc (FH) VLPs showed significantly reduced ability to activate TLR5 
or induce systemic interleukin-6 release as compared to FljB. FH VLPs also failed to 
significantly increase rectal temperature of mice, while FljB could significantly increase rectal 
temperature of mice. These data indicated systemic safety of FljB could be significantly 
improved by high-density display on HBc VLP surface. Besides improved safety, FH VLPs and 
FljB similarly boosted co-administered ovalbumin immunization and FH VLPs were found to 
induce two-fold higher anti-FljB antibody titer than FljB. These data indicated preserved 
adjuvant potency and improved immunogenicity after high-density display of FljB on HBc VLP 
surface. Consistent with the high immunogenicity, FH VLPs were found to be more efficiently 
taken up by bone marrow-derived dendritic cells (BMDCs) and stimulate more potent DC 
maturation than FljB. Lastly, FH VLPs were found to be a more immunogenic carrier than FljB, 
HBc VLPs, or the widely used keyhole limpet hemocyanin for nicotine vaccine development 
with good local and systemic safety. Our data support FH VLPs to be a potentially safer and 
more immunogenic carrier than FljB for vaccine development. 
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Introduction 
Flagellin is the major component of flagellar filament and has 4 structural domains (D0, D1, D2, 
and D3) [1]. D0/D1 domains form filament core and are composed of highly conserved N- and 
C-termini of flagellin [1]. D2/D3 domains form outer surface of filament and are composed of 
highly variable central region of flagellin [1]. Extracellular flagellin can be recognized by toll-
like receptor (TLR) 5 and intracellular flagellin can be recognized by NOD-like receptor (NLR) 
family, apoptosis inhibitory protein 5 (NAIP5) to initiate NLR family CARD domain containing 
4 (NLRC4) inflammasome activation [2, 3]. D1 domain contributes to TLR5 binding and 
filament formation and D0 domain contributes to NAIP5 recognition and NLRC4 inflammasome 
activation [4-6]. TLR5 binding leads to NFκB activation and release of pro-inflammatory 
cytokines, such as interleukin (IL)-6, while NLRC4 inflammasome activation leads to Caspase-1 
activation [7]. 
 
Flagellin has been explored as vaccine adjuvants and carriers [8]. FljB and FliC from gram-
negative Salmonella enterica serovar Typhimurium (S. Typhimurium) were actively explored for 
recombinant and conjugate vaccine development [9]. Foreign antigens can be co-administered 
with flagellin or inserted to its N- or C-terminus or highly variable D3 region to elicit potent 
immune responses [8]. Pre-existing immunity against flagellin showed no significant impacts on 
its adjuvant effects and potent adjuvant effects could be induced at relatively low doses prior to 
induction of maximal innate immunity [10, 11]. Despite these advantages, two flagellin-based 
influenza vaccines (VAX125 and VAX102) induced systemic adverse reactions especially at 
high doses in clinical studies [12, 13]. Both vaccines dose-dependently increased serum c-
reactive protein (CRP) levels and some patients with systemic adverse reactions were 
accompanied with elevated serum IL-6 levels [12, 13]. Another flagellin-based influenza vaccine 
(VAX128) also dose-dependently increased serum CRP levels in old people and 4.8% subjects 
experienced at least 4-fold increase of serum IL-6 [14]. Increase of serum CRP and IL-6 levels 
were also observed in a recent clinical trial of a different flagellin-based influenza vaccine 
(VAX2012Q) [15]. Considering TLR5 activation leads to IL-6 secretion that in turn activates 
CRP release [12-15], over activation of TLR5 on various types of lymphoid and non-lymphoid 
cells may contribute to systemic adverse reactions associated with flagellin-based vaccines [8, 
16]. 
 
Hepatitis b core protein (HBc) self-assembles into virus-like particles (VLPs) and c/e1 loop of 
HBc provides an ideal site for high-density display of antigenic epitopes on VLP surface [17-19]. 
Owing to its small size, short antigenic epitopes are preferred over full-length proteins for high-
density display on HBc VLP surface upon c/e1 loop insertion. As of now, only two full-length 
proteins (green fluorescence protein (GFP, 238 aa) and outer surface protein C of the Lyme 
disease agent Borrelia burgdorferi (OspC, 189 aa)) with closely juxtaposed N- and C-termini 
were successfully displayed on HBc VLP surface via c/e1 loop insertion [20, 21]. Flagellin also 
has closely juxtaposed N- and C-termini based on its crystal structure (PDB code, 1UCU) and 
may be a good candidate for insertion into c/e1 loop of HBc without interference of its self-
assembly into VLPs. High-density display of flagellin on HBc VLP surface may embed D0/D1 
domains of flagellin in interior of VLPs and thus reduce its TLR5 activation ability and improve 
safety. At the same time, transition of flagellin from soluble to particulate form may increase its 
immunogenicity [22]. 
 
This study prepared high-density FljB-displayed HBc VLPs (FH VLPs) by insertion of full-
length FljB (506 aa) into c/e1 loop of HBc. FH VLPs showed significantly reduced ability to 
activate TLR5 and induce systemic IL-6 release than FljB. FljB but not FH VLP immunization 
was found to significantly increase rectal temperature of mice. Besides improved safety, FH 
VLPs showed similar adjuvant effects to FljB in boosting co-administered ovalbumin (OVA) 
immunization and FH VLPs induced more than two-fold higher anti-FljB antibody titer and FljB. 
Consistent with improved immunogenicity, FH VLPs could be more efficiently taken up by bone 
marrow-derived DCs (BMDCs) and stimulate more potent BMDC maturation than FljB. Lastly, 
we found FH VLPs were a more immunogenic carrier than FljB, HBc VLPs, and the widely used 
keyhole limpet hemocyanin (KLH) for nicotine vaccine development. 
 
 
  
Materials and methods 
Reagents 
All enzymes used in molecular cloning experiments were purchased from New England Biolabs 
(Ipswich, MA). Fluorescence-conjugated antibodies used in immunostaining and flow cytometry 
were purchased from Biolegend (San Diego, CA) or Thermo Fisher Scientific (Waltham, MA). 
HEK-Blue™ mTLR5 cell line (hkb-mtlr5) and flagellin control (FLA-ST, Ultrapure) were 
purchased from Invivogen (San Diego, CA). Recombinant murine granulocyte macrophage 
colony-stimulating factor (GM-CSF, 415-ML/CF) and IL-4 (404-ML/CF) were purchased from 
R & D Systems (Minneapolis, MN). CpG 1826 was synthesized by Trilink Biotechnologies (San 
Diego, CA). 8-well chamber slides (Nunc™ Lab-Tek™ Chamber Slide™, 177442), 
LysoTracker™ Deep Red (L12492), Hoechst 33342 (H1399), RIPA buffer (89900), protease and 
phosphatase inhibitor cocktail (78442), Alum (Imject Alum, 77161), KLH (Imject mcKLH, 
77600), bovine serum albumin (BSA, Imject, 77110) were purchased from Thermo Fisher 
Scientific (Waltham, MA). Antifade fluorescence mounting medium (ab104135) was purchased 
from Abcam (Cambridge, MA). 
 
Animals 
BALB/c and C57BL/6 mice (male, 6-8 weeks old) were purchased from Charles River 
Laboratories (Wilmington, MA). MyD88 knockout (KO) mice were purchased from Jackson 
Laboratory (Bar Harbor, ME) and self-bred for use in this study. Animals were housed in animal 
facilities of University of Rhode Island. Mice were anesthetized by intraperitoneal injection of 
ketamine (80 mg/kg) and xylazine (10 mg/kg) for hair removal and intradermal (ID) 
immunization. All animal procedures were approved by Institutional Animal Care and Use 
Committee of University of Rhode Island.  
 
Recombinant plasmid construction 
FljB gene of S. Typhimurium strain LT2 and partial HBc gene encoding 1-149 region of adw 
subtype were synthesized by Thermo Fisher Scientific. Forward primer (5’-
GCGCATATGGGCAGCAGCCATCATCATCATCATCAC 
AGCAGCGGCCTGGTGCCGCGCGGCAGCGCACAAGTAATCAAC-3’) containing Nde I 
recognition site (underlined), his-tag sequence (italicized), and thrombin cleavage site 
(underlined and italicized) and reverse primer (5’-GCGCTCGAGTTAACGTAACAGAGAC 
AGCACG-3’) containing Xho I recognition site (underlined) and stop codon (italicized) were 
used to amplify FljB gene.  Forward primer (5’-GCGCATATGGACATTGACCCGTATA 
AAG-3’) containing Nde I recognition site (underlined) and reverse primer (5’-GCGCTCGAG 
AACAACAGTAGTTTCCGG-3’) containing Xho I recognition site (underlined) were used to 
amplify HBc (1-149) gene.    Polymerase chain reaction (PCR) products of FljB and HBc genes 
were subjected to Xho I and Nde I digestion and then ligated into pET-29a vector digested with 
the same enzymes.  
 
Overlapping PCR was used to insert FljB gene into c/e1 loop of HBc (A80-S81), as illustrated in 
Fig.1B. A flexible linker GGGGSGGGGS or (G4S)2 was inserted between HBc and FljB 
sequences to increase protein chain flexibility during refolding. In more detail, the 
aforementioned forward primer of HBc and reverse primer (5’-TGCTGGATCTTCCAAATTA 
CTTCCCACC-3’) were used to amplify HBc (1-80), forward primer (5’- GGTGGGAAGTA 
ATTTGGAAGATCCAGCAGGTGGTGGTGGTAGTGGTGGTGGTGGTAGT GCACAAGT 
AATCAACACTAACAGT-3’) containing overlapping sequence to reverse primer of HBc 
(underlined), linker sequence (italicized), and N-terminal FljB sequence (no formatting), and 
reverse primer (5’-ACGTAACAGAGACAGCACGTTCTGCGGG-3’) were used to amplify 
FljB gene. Forward primer (5’-CCCGCAGAACGTGCTGTCTCTGTTACGTGGTGGTGG 
TGGTAGTGGTGGTGGTGGTAGTTCCCGGGAATTAGTAGTCAGCTATGTC-3’) containing 
overlapping sequence to reverse primer of FljB gene (underlined), linker sequence (italicized), 
and HBc (81-89) sequence (no formatting), and the aforementioned reverse primer of HBc were 
used to amplify HBc (81-149) gene. The above 3 PCR products were mixed at 1:1:1 molar ratio 
and allowed to anneal and extend. Forward and reverse primers of HBc (1-149) were used to 
amplify FljB-HBc gene sequence and PCR products were purified, digested with Xho I and Nde 
I, and ligated into pET-29a vector. Successful ligation was confirmed with sequencing after 
transformation of ligated pET-29a vector into competent DH5α cells.  
 
Expression and purification of FljB-HBc, FljB, and HBc 
Bacterial BL21 cells were transformed with FljB-HBc, FljB, and HBc plasmids after sequence 
confirmation and grown in LB medium. Overnight bacteria culture was diluted 1:100 in fresh LB 
medium and grown to OD600nm reaching 0.8-1.0. Isopropyl-β-D-thiogalactoside (IPTG) was 
added to stimulate protein expression. Bacteria cells were harvested 3 hours later and 
centrifuged. Bacteria pellets were resuspended in lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 
pH 8.0) followed by sonication and centrifugation. Supernatants were used to purify FljB under 
native condition, while inclusion bodies were used to purify FljB-HBc and HBc under denatured 
conditions. In more detail, supernatants from FljB-expressing bacteria were loaded onto a Ni-
NTA column, washed, and eluted with 0.3 M imidazole. Inclusion bodies from HBc and FljB-
HBc-expressing bacteria were washed and dissolved in above lysis buffer supplemented with 8M 
Urea. After centrifugation, supernatants were loaded onto a Ni-NTA column, washed, and eluted 
with 0.3 M imidazole. FljB samples were dialyzed against phosphate-buffered saline (PBS), 
while HBc and FljB-HBc samples were dialyzed against PBS with reducing Urea concentrations 
(4, 2, and 0 M). FljB was subjected to thrombin cleavage to remove N-terminal his-tag via 
Thrombin CleanCleave™ Kit (RECOMT-1KT, Sigma). Purified proteins were subjected to 
SDS-PAGE analysis. Soluble proteins in FljB-HBc and HBc samples were removed by size-
exclusion column loaded with Sepharose CL-4B (17015001, GE Healthcare Life Science). 
 
Transmission electron microscopy (TEM) 
For negative staining TEM, FH VLP and HBc VLP samples were deposited on carbon/Formvar-
coated copper grids (01813-F, Ted Pella, Redding, CA) and then negatively stained with 2% 
uranyl acetate (22400, Electron Microscopy Sciences, Hatfield, PA). For immunogold labeling 
TEM, HBc VLPs and FH VLPs were deposited on carbon/Formvar-coated copper grids and then 
blocked with PBS supplemented with 1% BSA (blocking buffer). After that, VLP-deposited 
grids were incubated with 1:10 diluted anti-FljB antiserum or non-immune serum and then 
washed 3 times in blocking buffer. Grids were then incubated with 1:20 diluted 6 nm gold-
conjugated goat-anti-mouse secondary antibody (25123, Electron Microscopy Sciences, Hatfield, 
PA). After 3 times of wash in blocking buffer and 3 times of wash in water, grids were 
negatively stained with 2% uranyl acetate. TEM images were acquired with a JEM-2100F 
electron microscope (JEOL, Peabody, MA) at 200 kV. 
 
TLR5 activation assay 
Murine TLR5 and an inducible SEAP (secreted embryonic alkaline phosphatase) reporter gene-
co-transfected HEK293 cells (HEK-Blue™ mTLR5 cell line) were used to explore TLR5 
activation ability of FH VLPs following Manufacturer’s instructions. In brief, after cells reached 
~80% confluency, cells were harvested, adjusted to 140,000 cells/mL using HEK-Blue™ 
detection medium that contained a specific SEAP color substrate to facilitate the detection, and 
then seeded into 96-well plates (180 l/well). FH VLPs, FljB, FLA-ST, and HBc VLPs were 
added at final concentrations of 8, 40, 200, 1000 pM. Cells were incubated for 10 hours and 
OD620nm was read in a microplate reader to indicate relative TLR5 activation ability. 
 
Western Blotting 
Purified FljB-HBc, FljB, and HBc were subjected to western blotting analysis. In brief, proteins 
(10-50 ng) were separated in SDS-PAGE and then transferred to PVDF membrane. After 
blocking with 5% non-fat milk in TBST (Tris-buffered saline (TBS)/0.1% Tween 20, pH 7.6), 
PVDF membrane was incubated with 1:1000 diluted anti-FljB or anti-HBc antiserum in blocking 
buffer for 90 minutes. After 3 times of wash in TBST, PVDF membrane was incubated with 
horseradish peroxidase (HRP)-conjugated horse-anti-mouse secondary antibody (7076S, Cell 
Signaling Technology). After 3 times of wash in TBST, SuperSignal™ West Femto Maximum 
Sensitivity Substrate (34095, Thermo Fisher Scientific) was added and myECL imager (Thermo 
Fisher Scientific) was used for chemiluminescent imaging. To detect mature Caspase-1 p20 
band, stimulated BMDCs were lysed in RIPA buffer supplemented with protease and 
phosphatase inhibitor cocktail. The same amount of proteins in each group were separated in 
SDS-PAGE and then transferred to PVDF membrane. After blocking, PVDF membrane was 
incubated with 1 µg/mL mouse anti-Caspase-1 (p20) antibody (AG-20B-0042, Adipogen Life 
Sciences) followed by the same procedures as described above to detect Caspase-1 p20 subunit. 
To detect GAPDH expression, PVDF membrane was stripped in stripping buffer (62.5 mM Tris-
HCl, 2% SDS, 0.7% β-mercaptoethanol, pH 6.8) at 50˚C for 30 minutes. PVDF membrane was 
then incubated with rabbit anti-GAPDH antibody (D16H11, 5174S, Cell Signaling Technology) 
and HRP-conjugated goat-anti-rabbit secondary antibody (7074P2, Cell Signaling Technology) 
for GAPDH detection. 
 
Fluorescent dye conjugation 
Alexa Fluor 555 (AF555) was conjugated to FH VLPs, FljB, and HBc VLPs with AF555 NHS 
Ester (AF555, Invitrogen) based on Manufacturer’s instructions. In brief, AF555 was dissolved 
in DMSO at 10 mg/ml and 20 µl AF555 was added to 1 mg FH VLPs, FljB, and HBc VLPs in 
100 µl PBS. After 1 hour of reaction at room temperature, free AF555 was removed by dialysis 
against PBS. 
 
Antigen uptake and maturation of DCs 
Bone marrow was isolated from femur and tibia of C57BL/6 mice and cultured in the presence of 
recombinant murine GM-CSF (15 ng/ml) and IL-4 (10 ng/ml) as in our previous report [23]. 
Non-adherent immature BMDCs were harvested on day 6 and seeded at 1×106 cells/mL into 8-
well chamber slides. AF555-conjugated FH VLPs, FljB, and HBc VLPs were added at a final 
concentration of 70 nM of respective proteins. LysoTracker™ Deep Red (75 nM) was added 1.5 
hours later to stain acidic organelles and Hoechst 33342 (2 µg/mL) was added 2.5 hours later to 
stain cell nuclei. Cells were washed with PBS for 3 times at 3 hours and then fixed in 4% 
paraformaldehyde for 20 minutes. After removal of chamber wells, chamber slides were 
mounted with antifade fluorescence mounting medium followed by confocal imaging under 
Nikon Eclipse Ti2 inverted confocal microscope. For flow cytometry analysis, BMDCs were 
seeded at 1×106 cells/mL in 96-well plates and then incubated with AF555-conjugated FH VLPs, 
FljB, and HBc VLPs at the above concentration. Cells were harvested 3 and 20 hours later, 
stained with fluorescence-conjugated anti-CD11c (N418), and then subjected to flow cytometry 
analysis of percentage of AF555+ cells in CD11c+ cells in BD FACSVerse. For maturation study, 
immature BMDCs were seeded at the same concentration to 96-well plates and stimulated with 
FH VLPs, FljB, and HBc VLPs at the above concentration for 20 hours. Cells were stained with 
fluorescence-conjugated anti-CD11c (N418), anti-CD40 (3/23), anti-CD80 (16-10A1), and anti-
CD86 (GL-1) followed by flow cytometry analysis of surface expression of CD40, CD80, and 
CD86 in BD FACSVerse. To explore whether FH VLPs stimulated in vivo DC maturation, 5 µg 
FH VLPs, 3.7 µg FljB, and 1.2 µg HBc VLPs (equal moles) were intradermally injected into 
lateral back skin of C57BL/6 mice. Skin was dissected 24 hours later and single-cell suspensions 
were prepared as in our previous report [24]. Skin cells were then similarly stained with 
fluorescence-conjugated anti-CD11c, anti-CD40, anti-CD80, and anti-CD86 followed by flow 
cytometry analysis as above. 
 
Immunization 
To explore adjuvant effects of FH VLPs and FljB, BALB/c mice were intradermally immunized 
with 10 µg OVA alone or in the presence of 3 µg FH VLPs or 2.2 µg FljB (same mole). 
Immunization was repeated 3 weeks later. To compare relative immunogenicity of FH VLPs and 
FljB to induce anti-FljB antibodies and impacts of MyD88 on anti-FljB antibody production, 
wild type (WT) and MyD88 KO mice were intradermally immunized with 5.0 µg FH VLPs or 
3.7 µg FljB (same mole). Immunization was repeated 3 weeks later. To compare relative 
immunogenicity of FljB-Nic to KLH-Nic, BALB/c mice were intradermally immunized with 3 
µg FljB-Nic or KLH-Nic. To compare relative immunogenicity of HBc-Nic to KLH-Nic, 
BALB/c mice were intradermally immunized with 3 µg HBc-Nic or KLH-Nic. To compare 
relative immunogenicity of FH-Nic to KLH-Nic and whether chemical adjuvants could boost 
FH-Nic immunization, BALB/c mice were intradermally immunized with 3 µg FH-Nic in the 
presence or absence of Alum (1:1 volume ratio), 30 µg CpG 1826, or combinatorial CpG/Alum 
adjuvant, or intradermally immunized with 3 µg KLH-Nic or left non-immunized. Adjuvants 
were simply mixed with vaccines before delivery in this study. Immunization was repeated three 
times at a 3-week interval.  
 
Serum antibody titer 
A small volume of blood (25-50 µl) was collected 3 weeks after immunization. Serum antibody 
titer was measured by enzyme-linked immunosorbent assay (ELISA) by coating 1 µg/ml FljB, 
HBc VLPs, or BSA-conjugated nicotine (BSA-Nic) onto 96-well ELISA plates as in our 
previous report [25]. For detection of isotype IgG1 and IgG2a or IgG2c antibody titer, HRP-
conjugated anti-mouse IgG1, IgG2a or IgG2c secondary antibodies were used. 
 
Cytokine levels 
Serum IL-6 levels were measured by Mouse IL-6 ELISA Ready-SET-Go kit (88-7064-88, 
eBioscience). Supernatant IL-12 levels were measured by Mouse IL-12 p70 ELISA Ready-SET-
Go kit (50-172-51, eBioscience). 
 
Nicotine challenge and tissue nicotine detection 
Mice were weighed and intravenously challenged with 0.03 mg/kg nicotine. Five minutes later, 
brain and trunk blood were collected, and tissue nicotine was extracted following methods 
established by Pentel et. al. [26]. Brain and serum nicotine levels were quantified by gas 
chromatography-mass spectrometry and expressed as nicotine amount per gram of brain or per 
milliliter of serum as in our previous report [25]. 
 
Endotoxin removal 
Endotoxin in FH VLPs, FljB, and HBc VLPs was removed by a commercial endotoxin-removal 
column (20344, Thermo Fisher Scientific) or Pierce™ High Capacity Endotoxin Removal Resin 
(88270, Thermo Fisher Scientific) according to Manufacturer’s Instructions. Remaining 
endotoxin levels were quantified by Pierce™ LAL Chromogenic Endotoxin Quantitation Kit 
(88282, Thermo Fisher Scientific) or Pierce™ Chromogenic Endotoxin Quant Kit (A39552, 
Thermo Fisher Scientific) and found to be below 2.5 ng/mg. 
 
Nicotine hapten conjugation 
Conjugation of nicotine hapten (CMUNic) to FH VLPs, FljB, HBc VLPs, KLH, and BSA 
referred to our previous study [25]. In brief, 1 mg CMUNic was activated with 5 mg N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDAC, E1769, Sigma) at room 
temperature for 10 minutes. FH VLPs, FljB, HBc VLPs, KLH, and BSA (1 mg) was added to the 
above mixture and kept at room temperature for 3 hours with continuous stirring. Nicotine 
conjugates were then dialyzed against PBS for 3 times. 
 
Antibody avidity index 
Seram samples were individually analyzed for antibody avidity by competitive ELISA as 
reported [27]. In brief, serum samples were subjected to 10-fold serial dilutions and added to 96-
well plates coated with BSA-Nic. After 90 minutes of incubation, NH4SCN (2M) was added to 
elute loosely bound antibody. ELISA plates were then incubated with HRP-conjugated sheep-
anti-mouse secondary antibody (NA931, GE Healthcare Life Sciences) followed by addition of 
TMB substrate. Reactions were stopped by 3M H2SO4 and OD450nm was read in a microplate 
reader. OD450nm against log dilutions of immune sera was plotted in the presence or absence of 
NH4SCN. Areas under the curve were then calculated. Ratio of the area under the curve in the 
presence versus absence of NH4SCN was calculated and used as antibody avidity. 
 
Statistics 
Values were expressed as Mean ± SEM (standard error of the mean). Student’s t-test was used to 
compare differences between groups. One-way analysis of variance (ANOVA) with Tukey’s or 
Bonferroni’s multiple comparison test was used to compare differences for more than two groups 
or otherwise specified. P value was calculated by PRISM software (GraphPad, San Diego, CA) 
and considered significant when it was less than 0.05.  
Results 
FljB-HBc self-assembles into VLPs 
C/e1 loop of HBc provides an ideal site for insertion of foreign antigens for display on VLP 
surface [17-19]. As shown in Fig.1A, c/e1 loop of HBc is localized in the flexible region of two 
α-helices and form the tip of spikes on VLP surface. N- and C-termini of S. Typhimurium FliC is 
proximate to each other based on its crystal structure (Fig.1A). S. Typhimurium FljB shares high 
N- and C-terminal homology with FliC (Suppl. Fig.1) and is expected to also have closely 
juxtaposed N- and C-termini. As of such, insertion of FljB into c/e1 loop of HBc is less likely to 
pose significant steric hindrance to self-assembly of HBc into VLPs, thus allowing high-density 
display of FljB on HBc VLP surface, as depicted in Fig.1A. DNA was constructed to express 
full-length FljB between A80 and S81 of c/e1 loop of HBc and (G4S)2 linker was inserted 
between FljB and HBc sequences to increase protein chain flexibility (Fig.1B). Recombinant 
FljB-HBc, FljB, and HBc with a theoretical molecular weight of 71.3, 52.5, and 17.7 kDa, 
respectively, were expressed in E. coli, purified, refolded, and analyzed by SDS-PAGE (Fig.1C). 
Western blotting analysis confirmed the presence of both FljB and HBc in FljB-HBc fusion 
protein. As shown in Fig.1D, FljB-HBc and FljB but not HBc samples showed positive bands at 
the right position when PVDF membrane was blotted with anti-FljB antiserum. As shown in 
Fig.1E, FljB-HBc and HBc but not FljB samples showed positive bands at the right position 
when PVDF membrane was blotted with anti-HBc antiserum. 
 
Fig.1 Expression and characterization of recombinant FljB-HBc, FljB and HBc 
A. Crystal structure of HBc and Flagellin in web-based 3D structure viewer (iCN3D) and depict 
of high-density FljB-displayed HBc VLPs. Protein data bank (PDB) codes used were 1QGT 
(HBc) and 1UCU (FliC). C/e1 loop (N74-L84) of HBc was highlighted in magenta. N- and C-
termini of HBc and FljB were labeled with letter N and C, respectively. B. Schematic of DNA 
construct for FljB-HBc fusion protein expression. Full-length FljB (1-506) flanked with (G4S)2 
linkers was inserted between A80 and S81 of c/e1 loop of HBc (1-149, Adw subtype). C. 
Recombinant FljB-HBc, FljB, and HBc were subjected to SDS-PAGE analysis. D-E. 
Recombinant FljB-HBc, FljB, and HBc were subjected to western blotting analysis. Anti-FljB 
antiserum was used to blot PVDF membrane in D and anti-HBc antiserum was used to blot 
PVDF membrane in E. 
 
 
Fig.2 Characterization of FH VLPs and HBc VLPs 
A. DLS and zeta potential measurements of FH and HBc VLPs. Particle size distributions were 
shown in the left. Particle size, PDI, and zeta potential were listed on the right. B. Representative 
TEM images of FH and HBc VLPs following negative staining. Arrows point to clearly small 
particles. Scale: 50 nm. C. Representative TEM images of FH VLPs following immunogold 
staining with anti-FljB antiserum (left) or non-immune serum (middle) or HBc VLPs following 
immunogold staining with anti-FljB antiserum (right). Arrows point to VLPs. Scale: 50 nm. D. 
Particle size of FH and HBc VLPs after immunogold staining in C was measured in Image J 
(n=32-46). One-way ANOVA with Tukey’s multiple comparison test was used to compare 
differences between groups in D. ***: p<0.001. 
 
Next, FljB-HBc and HBc samples were subjected to dynamic light scattering (DLS) analysis in 
Zetasizer Nano ZS (Malvern). As shown in Fig.2A, FH and HBc VLPs had a size of 44 and 37 
nm, respectively, with a PDI value less than 0.3 for both particles. Zeta potential was also 
measured and found to be -25 mV for FH VLPs and -23.6 mV for HBc VLPs at neutral pH 
(Fig.2A), in line with the theoretical isoelectric point (pI) of 5.03 and 5.73 for FljB-HBc and 
HBc, respectively (ExPASy). Slightly more net negative charge of FH VLPs can be explained by 
the slightly lower pI of FljB-HBc. TEM analysis found both samples contained round-shaped 
particles less than 50 nm in diameter (Fig.2B). We further found HBc and FH VLPs contain two 
particle sizes, in line with report that HBc could self-assemble into particles with two icosahedral 
symmetries (T = 3 and T = 4) [28]. T = 3 and T = 4 particles contain 180 and 240 copies of HBc, 
respectively, with T =3 particles slightly smaller than T =4 particles [28]. More details about 
assembling symmetry of FH VLPs remain to be explored with high-resolution cryo-electron 
microscope or scanning transmission electron microscope [28]. As compared to HBc VLPs, FH 
VLPs showed brighter signals following negative staining and TEM, which may be caused by 
reduced scattering of electron beams due to dense FljB coating [29].  
 
We further conducted immunogold labeling TEM to verify the presence of FljB on FH VLP 
surface. As shown in Fig.2C, FH VLPs showed positive immunogold signals after staining with 
anti-FljB antiserum but not non-immune serum. As a negative control, HBc VLPs showed no 
immunogold signals after immunogold staining with anti-FljB antiserum (Fig.2C). These results 
clearly indicated the presence of FljB on HBc VLP surface. We further measured particle size of 
the different VLPs after immunogold labeling. As shown in Fig.2D, FH VLPs had a size of 46 
nm after immunogold staining with anti-FljB antiserum and a size of only 30 nm after 
immunogold staining with non-immune serum. Such a difference is likely to be caused by the 
immunogold staining that revealed FljB on FH VLP surface. Interestingly, the distance between 
Leu493 (end of D0 domain) and Ala184 (middle of the D2/D3 domain) of FliC was about 15 nm 
(Suppl. Fig.2), which matched very well with the above size difference. HBc VLPs had a size of 
24 nm after immunogold staining with anti-FljB antiserum (Fig.2D). In TEM studies without 
immunogold staining, we failed to observe spikes on FH VLP surface, while spikes were found 
in outer surface protein C-displayed HBc VLP surface [21]. This may simply reflect the 
resolution difference of electron microscope equipment. Immunogold labeling TEM revealed 
surface-displayed FljB and allowed us to more accurately measure FH VLP size, which was 
much bigger than HBc VLPs (Fig.2D). High-resolution TEM or cryo-EM would be needed to 
reveal the ultrafine surface structure of FH VLPs. 
 
Impaired TLR5 and Caspase 1 activation while preserved adjuvant effects 
FljB activates both TLR5 and NLRC4 inflammasome. The ability of FH VLPs to activate TLR5 
and NLRC4 inflammasome was then explored and compared with FljB and FLA-ST. FLA-ST is 
ultrapure FliC purified from S. Typhimurium based on manufacturer’s description. HEK293 cells 
co-transfected with murine TLR5 and SEAP reporter gene were incubated with FH VLP, FljB, 
and FLA-ST at different molar concentrations of respective proteins. As shown in Fig.3A, FH 
VLPs showed much weakened ability to activate TLR5 than FljB and FLA-ST. The lowest 
concentration of FljB, FLA-ST, and FH VLPs to significantly activate TLR5 was 8, 40, and 1000 
pM, respectively (Fig.3A), indicating 25-fold reduced TLR5 activation ability of FH VLPs as 
compared to FLA-ST and more than 100-fold reduced TLR5 activation ability of FH VLPs as 
compared to FljB. Next, the ability of FH VLPs to activate NLRC4 inflammasome was explored. 
NLRC4 inflammasome is a multi-protein complex, the activation of which cleaves pro-Caspase-
1 to form p10/p20 heterodimer. Here we directly analyzed Caspase-1 activation following 
incubation of BMDCs with FH VLPs, FljB, and FLA-ST to reflect their NLRC4 inflammasome 
activation ability. As shown in Fig.3B, Caspase-1 p20 subunit could be readily detected after 
BMDC incubation with FljB and FLA-ST but not FH VLPs. This result indicated significant loss 
of NLRC4 inflammasome activation ability of FH VLPs. 
 
Considering FljB doesn’t require strong activation of innate immunity to exert its adjuvant 
effects, we explored adjuvant effects of FH VLPs on boosting co-administered OVA 
immunization in BALB/c mice. As shown in Fig.3C, FH VLPs but not FljB significantly 
increased anti-OVA antibody titer after prime. FH VLPs also similarly increased anti-OVA 
antibody titer to FljB after boost (Fig.3D). To explore whether adjuvant effects of FH VLPs 
could be observed in another species of mice and whether FH VLPs could dose-dependently 
increase OVA-induced antibody production, C57BL/6 mice were intradermally immunized with 
OVA alone or in the presence of increasing FH VLP doses (3, 10, and 30 µg). As shown in 
Suppl. Fig.3A, low dose but not medium or high dose of FH VLPs significantly increased anti-
OVA antibody titer in C57BL/6 mice. Furthermore, low-dose FH VLPs more significantly 
increased anti-OVA IgG2c antibody titer than IgG1 antibody titer (Suppl. Fig.3B-C). Mouse 
immunization studies indicated FH VLPs possessed potent adjuvant effects despite the lack of 
significant TLR5 and NLRC4 inflammasome activation abilities. 
 
Fig.3 Impaired TLR5 and Caspase 1 activation of FH VLPs 
A. TLR5 activation ability of FH VLPs, FljB, and FLA-ST. HEK293 cells co-transfected with 
TLR5 and SEAP reporter gene were incubated with FH VLPs, FljB, and FLA-ST in triplicate at 
8, 40, 200, 1000 pM of respective proteins to keep equal flagellin contents across groups at each 
treatment concentration. OD620nm was read 10 hours later to indicate relative TLR5 activation 
ability. B. Caspase-1 activation ability of FH VLPs, FljB, and FLA-ST. BMDCs were incubated 
with FH VLPs, FljB, and FLA-ST at 70 nM of respective protein levels in duplicate for 24 hours. 
Expression of pro-Caspase-1, Caspase-1 (p20), and house-keeping gene GAPDH was analyzed 
by western blotting. C-D. BALB/c mice were intradermally immunized with 10 µg OVA alone 
or in the presence of 3 µg FH VLPs or FljB. Immunization was repeated 3 weeks later. Serum 
anti-OVA antibody titer was measured 3 weeks after prime (C) and boost (D). Two-way 
ANOVA with Bonferroni’s post-test was used to compare differences between groups at each 
protein concentration in A. One-way ANOVA with Tukey’s multiple comparison test was used 
to compare differences between groups in C and D. n=5 in C and D. *: p<0.05; ***: p<0.001. 
NS: not significant. 
 
More efficient uptake of FH VLPs than FljB by BMDCs 
Good vaccine carriers need to be efficiently taken up by antigen presenting cells (APCs). Uptake 
of FH VLPs and FljB was then explored in BMDCs. Soluble proteins are often endocytosed and 
sorted through early endosomes, late endosomes, and lysosomes[30]. Particulate antigens are 
often phagocytosed and end up in phagolysosomes formed by fusion of phagosomes and 
lysosomes[30]. Considering lysosomes and phagolysosomes have a pH of 4-4.5 [30], 
LysoTracker capable of staining acidic organelles was used to stain both structures in this study. 
BMDCs were incubated with AF555-conjugated FH VLPs, FljB, and HBc VLPs at equal molar 
concentrations of respective proteins. FH VLPs showed more significant uptake than FljB as 
evidenced by much stronger AF555 signals in FH VLP group than FljB group (Antigen, Fig.4A). 
We further found the majority of AF555 signals in both FH VLP and FljB groups overlapped 
with LysoTracker signals (Merged, Fig.4A). HBc VLPs were also included for comparison and 
we found BMDCs could also significantly take up HBc VLPs into lysosomes (Fig.4A). BMDC 
uptake of FH VLPs, FljB, and HBc VLPs at equal molar concentrations was also explored by 
flow cytometry. As shown in Fig.4B-C, percentage of AF555+ DCs was 25% in FH VLP group, 
19% in HBc VLP group, 8% in FljB group, and less than 1% in medium only group. Percentage 
of AF555+ DCs was significantly higher in FH VLP group than that in FljB group (Fig.4C). 
Percentage of AF555+ DCs was also significantly higher in FH VLP group than that in HBc VLP 
group (Fig.4C). The same trend was also observed at 20 hours of incubation (Fig.4D). The same 
experiment was repeated by incubation of BMDCs with equal fluorescence intensities of FH 
VLPs, FljB, and HBc VLPs, equivalent to ~1:2:5 molar concentrations of FljB-HBc, FljB, HBc. 
We still observed significantly increased uptake of FH VLPs as compared to soluble FljB 
although HBc VLPs showed the most significant uptake this time (Suppl. Fig.4). These data 
indicated FH VLPs could be more efficiently taken up by BMDCs than FljB.  
 
Fig.4 More efficient uptake of FH VLPs than FljB 
A. BMDCs were incubated with AF555-labeled FH VLPs, FljB, and HBc VLPs at equal molar 
concentrations (70 nM) of respective proteins, equivalent to ~5:2.5:1 fluorescence intensity, in 8-
well chamber slides. LysoTracker and Hoechst 33342 were added 1.5 and 2.5 hours later. Cells 
were subjected to fluorescence confocal imaging 3 hours later. Scale: 50µm. B-D. BMDCs were 
incubated with AF555-labeled FH VLPs, FljB, and HBc VLPs as in A in 96-well plates. Cells 
were harvested 3 and 24 hours later, stained with fluorescence-conjugated anti-CD11c followed 
by flow cytometry analysis. Cells were first gated based on SSC and FSC and then based on 
CD11c expression. Representative dot plots of percentage of AF555+ DCs at 3 hours were shown 
in B. Percentage of AF555+ DCs at 3 and 20 hours was shown in C and D, respectively. n=5. 
One-way ANOVA with Tukey’s multiple comparison test was used to compare differences 
between groups. *: p<0.05; ***: p<0.001. Experiments were repeated twice with similar results. 
 
FH VLPs stimulate more potent DC maturation than FljB 
Besides efficient uptake, stimulation of DC maturation by vaccine carriers is also crucial to elicit 
potent vaccine-specific immune responses. We then explored the relative ability of FH VLPs to 
stimulate BMDC maturation to FljB, FLA-ST, and HBc VLPs. In brief, BMDCs were stimulated 
with FH VLPs, FljB, FLA-ST, and HBc VLPs at equal molar concentrations of respective 
proteins. Surface expression of costimulatory molecules CD40, CD80, and CD86 was explored 
20 hours later. We found BMDCs could be divided into two populations based on CD40 
expression: CD40high (CD40hi) and CD40low (CD40lo), as shown in Fig.5A. MFI of CD40, CD80, 
and CD86 was compared among groups. We found MFI of CD40 was significantly increased in 
FH VLP group but not in FljB, FLA-ST, or HBc VLP group when compared to that in medium 
only group (Fig.5B). MFI of CD40 in FH VLP group was also significantly higher than that in 
FljB, FLA-ST, and HBc VLP group (Fig.5B). FH VLPs and FLA-ST slightly increased MFI of 
CD80 and CD86 (Fig.5C-D). MFI of CD80 and CD86 in FH VLP and FLA-ST groups was 
significantly higher than that in HBc VLP group but not medium only group (Fig.5C-D). MFI of 
CD86 in FljB group was also significantly higher than that in HBc VLP group (Fig.5D). Next, 
we compared percentage of CD40hi, CD80hi, and CD86hi DCs among the different groups. We 
found percentage of CD40hi, CD80hi, and CD86hi DCs was significantly higher in FLA-ST group 
than HBc VLP group and percentage of CD40hi DCs was significantly higher in FH VLP group 
than HBc VLP group (Fig.5E-G). The above results indicated FH VLPs were the most potent 
stimulator to increase surface expression of costimulatory molecules, among which CD40 
expression showed the most significant increase. Although FH VLPs could stimulate BMDC 
maturation, the ability of FH VLPs to stimulate BMDC maturation was much weaker than LPS 
(data not shown). The inability of FljB to significantly stimulate murine BMDC maturation was 
in line with previous report [31]. 
 
Fig.5 FH VLPs stimulate DC maturation in vitro 
BMDCs were incubated with FljB, FLA-ST, HBc VLPs, and FH VLPs in triplicate at equal 
molar concentrations (70 nM). Cells were harvested 20 hours later and stained with fluorescence-
conjugated anti-CD11c, CD86, CD80, CD40 antibodies followed by flow cytometry analysis. 
Cells were first gated based on SSC and FSC and then based on CD11c expression. CD11c+ cells 
were analyzed for expression of CD40, CD80, and CD86. A. Representative histogram of CD40 
expression and percentage of CD40hi DCs. B-D. MFI of CD40 (B), CD80 (C), and CD86 (D) in 
CD11c+ DCs. E-G. Percentage of CD40hi (E), CD80hi (F), and CD86hi (G) in CD11c+ DCs. One-
way ANOVA with Bonferroni’s multiple comparison test was used to compare differences 
between groups. *: p<0.05; **: p<0.01; ***: p<0.001. Experiments were repeated twice with 
similar results. 
 
Next, we explored whether FH VLPs could also stimulate DC maturation in vivo. To explore 
this, C57BL/6 mice were intradermally injected with FH VLPs, FljB, and HBc VLPs. Skin was 
dissected 24 hours later for exploration of CD40, CD80, and CD86 expression on CD11c+ DCs. 
As shown in Fig.6A-B, percentage of CD40hi cells in CD11c+ DCs was significantly increased in 
FH VLP but not FljB or HBc VLP group when compared to that in PBS group. MFI of CD40 
was also significantly increased in FH VLP but not FljB or HBc VLP group when compared to 
that in PBS group (Fig.6C). As in intro studies, no significant increase of MFI of CD80 or CD86 
was found in FH VLPs, FljB, or HBc VLPs when compared to that in PBS group (Fig.6D-E). 
These results indicated FH VLPs could also significantly increase CD40 expression and 
stimulate DC maturation in vivo. 
 
Fig.6 FH VLPs stimulate DC maturation in vivo 
Lateral back skin of C57BL/6 mice was intradermally injected with 5 µg FH VLPs, 3.7 µg FljB, 
and 1.2 µg HBc VLPs (equal moles) in 20 µl or an equal volume of PBS to serve as control. Skin 
was dissected 24 hours later. Single-cell suspensions were prepared and stained with 
fluorescence-conjugated anti-CD11c, CD40, CD80, and CD86 antibodies followed by flow 
cytometry analysis. Cells were first gated based on FSC and SSC and then based on CD11c 
expression. CD11c+ cells were analyzed for CD40, CD80, and CD86 expression. A. 
Representative dot plots showing percentage of CD40hi DCs. B. Comparison of percentage of 
CD40hi DCs among different groups. C-E. MFI of CD40 (C), CD80 (D), and CD86 (E) in 
CD11c+ DCs. n=4. One-way ANOVA with Bonferroni’s multiple comparison test was used to 
compare differences between groups. *: p<0.05; NS: not significant. 
 
FH VLPs are more immunogenic than FljB 
More efficient uptake and stimulation of DC maturation indicated FH VLPs might have 
improved immunogenicity as compared to FljB. To prove this, mice were immunized with FH 
VLPs and FljB (equal moles) and anti-FljB antibody responses were then measured and 
compared between groups. Flagellin was reported to mainly induce Th1-biased IgG1 antibody 
responses with high dependence on MyD88 [32, 33]. To explore FH VLP-induced antibody 
isotype and the dependence on MyD88, MyD88 KO mice were also included in above 
immunization studies. As shown in Fig.7A, FH VLPs induced 2.2-fold higher anti-FljB antibody 
titer than FljB. Lack of MyD88 almost completely abrogated FljB-induced antibody production 
but only partially inhibited FH VLP-induced anti-FljB antibody production (Fig.7A). FH VLP 
and FljB-induced isotype IgG1 and IgG2c antibody titer was also compared. As shown in 
Fig.7B, FljB was found to induce strong IgG1 and weak IgG2c antibody titer, hinting the 
induction of Th2-biased antibody responses. Lack of MyD88 almost completely abrogated FljB-
induced IgG1 and IgG2c antibody production (Fig.7B). In comparison, FH VLPs induced strong 
anti-FljB IgG2c and weak IgG1 antibody titer (Fig.7C), hinting the induction of Th1-biased 
antibody responses. Lack of MyD88 partially reduced FH VLP-induced IgG2c antibody 
production and showed no significant effects on FH VLP-induced IgG1 antibody production 
(Fig.7C). Due to the crucial role of IL-12 in skewing Th1-biased immune responses [34], we 
further measured IL-12 levels in BMDC stimulation studies and found FH VLPs but not FljB or 
FLA-ST stimulated significant IL-12 release (Suppl. Fig.5). This result at least partially 
explained strong induction of Th1-biased IgG2c antibody responses by FH VLPs. We further 
measured anti-HBc antibody titer and found FH VLPs failed to induce significant anti-HBc 
antibody production (Fig.7D), which was most likely due to the embedding of HBc in interior of 
FH VLPs. The above studies indicated FH VLPs were more immunogenic than FljB in 
stimulation of anti-FljB antibody production. 
 
Fig.7 FH VLPs induce more potent anti-FljB antibody responses than FljB 
WT and MyD88 KO mice were intradermally immunized with 5 µg FH VLPs or 3.7 µg FljB 
(equal moles). Immunization was repeated 3 weeks later. Serum antibody titer was measured 3 
weeks after boost. A. Serum anti-FljB IgG antibody titer after FH VLP and FljB immunization. 
B. Serum anti-FljB IgG1 and IgG2c antibody titer after FljB immunization. C. Serum anti-FljB 
IgG1 and IgG2c antibody titer after FH VLP immunization. D. Serum anti-HBc IgG titer after 
FH VLP and FljB immunization. n=6. One-way ANOVA with Bonferroni’s multiple comparison 
test was used to compare differences between groups. *, p<0.05; **, p<0.01; ***, P<0.001. NS: 
not significant. 
 
Improved systemic safety of FH VLPs 
Significantly reduced TLR5 activation ability implicated FH VLPs might have improved safety 
as compared to FljB. To prove this, we first measured serum IL-6 levels following FH VLP and 
FljB immunization of WT and MyD88 KO mice in above studies (Fig.7) considering IL-6 was 
linked to systemic adverse reactions of flagellin-based vaccines [12-15]. As shown in Fig.8A, 
serum IL-6 levels were significantly increased in WT mice at 6 hours after both FH VLP and 
FljB immunizations. Serum IL-6 levels returned to baseline levels 24 hours after FH VLP 
immunization and remained at relatively high levels 24 hours after FljB immunization in WT 
mice (Fig.8B). This result indicated FH VLPs induced more transient systemic IL-6 release than 
FljB. Interestingly, serum IL-6 levels failed to significantly increase after FH VLP or FljB 
immunization in MyD88 KO mice (Fig.8A-B), hinting crucial roles of MyD88 in mediating 
FljB-induced systemic IL-6 release. The relative ability of FH VLPs and FljB to induce systemic 
IL-6 release was also explored in BALB/c mice. FljB was found to significantly increase serum 
IL-6 levels at 6 hours, while FH VLPs failed to significantly increase serum IL-6 levels at the 
same time (Fig.8C). Serum IL-6 levels reduced to baseline levels 24 hours after immunization in 
both groups (Fig.8D). These results indicated FH VLPs had significantly reduced ability to 
induce systemic IL-6 release than FljB. 
 
Fig.8 Significantly improved systemic safety of FH VLPs 
A-B. Serum IL-6 levels were measured 6 (A) and 24 hours (B) after boost immunization of WT 
and MyD88 KO mice in Fig.7. Serum IL-6 levels before immunization was also measured 
(baseline). C-D. BALB/c mice were intradermally immunized with 5 µg FH VLPs or 3.7 µg FljB 
(equal moles). Immunization was repeated 3 weeks later. Serum IL-6 levels were measured just 
before boost immunization or 6 (C) and 24 hours (D) after boost immunization. E-G. C57BL/6 
mice were intradermally immunized with 20 µg FH VLPs or 14.8 µg FljB (equal moles). 
Immunization was repeated weekly for 3 weeks. Rectal temperature was measured right before 
each immunization (0 hour) or 24 hours after each immunization. n=6 in A-D and n=4 in E-G. 
One-way ANOVA with Bonferroni’s multiple comparison test was used to compare differences 
between groups in A-D. One-tailed student’s t-test was used to compared differences between 0 
and 24 hours within the same group in E-G. *, p<0.05; **, p<0.01; ***, P<0.001. NS: not 
significant. 
 
Besides induction of systemic IL-6 release, flagellin-based vaccines also induced systemic 
adverse reactions, like fever, in clinical trials [12-15]. Next, we compared the ability of FH VLPs 
and FljB to induce fever-related systemic adverse reactions in murine models. To explore this, 
C57BL/6 mice were intradermally immunized with increased doses of FH VLPs and FljB (20 
and 14.8 µg, respectively) weekly for 3 weeks and rectal temperature was measured right before 
and 24 hours after each immunization. Rectal temperature was measured with a mouse rectal 
temperature probe connected to PhysioSuite (Kent Scientific). Increase of FH VLP and Fljb 
doses in this study was because the previous FH VLP and FljB doses (5 and 3.7 µg, respectively) 
failed to significantly increase rectal temperature of mice (data not shown). As shown in Fig.8E-
G, FljB significantly increased rectal temperature by 0.275°C at 24 hours after the 1st and 2nd 
immunizations and increased rectal temperature by 0.625°C after the 3rd immunization. In 
contrast, FH VLPs failed to significantly increase rectal temperature after each immunization 
(Fig.7E-G). These data indicated FH VLPs had significantly reduced ability to increase rectal 
temperature of mice than FljB. We further found FH VLPs and FljB at the increased doses failed 
to induce microscopic tissue damage or body weight change as compared to PBS-injected mice 
(Fig.9), indicating the lack of systemic toxicity of both agents. 
 
Fig.9 Lack of overt toxicity of FH VLPs 
A. Body weight of C57BL/6 mice in Fig.7E-G was measured before immunization and one week 
after each immunization and compared among groups. B. Mice were sacrificed one week after 
the last immunization. Major organs, like heart, liver, spleen, lung, and kidney, were harvested, 
fixed in formalin, and then subjected to paraffin sectioning and H & E staining. Representative H 
& E-stained histological images were shown. Scale: 200 µm. 
 
More immunogenic FH VLPs than FljB, HBc VLPs or KLH for nicotine vaccine 
development 
The above studies indicated FH VLPs might be a more immunogenic and safer carrier than FljB 
for vaccine development. Next, nicotine vaccines were used as a model to compare relative 
immunogenicity and safety of FH VLPs to FljB, HBc VLPs, or the widely used KLH for nicotine 
vaccine development. Nicotine vaccines hold a great promise for anti-nicotine immunotherapy 
[35]. Despite the unsatisfied clinical outcomes of several nicotine vaccines (NicVAX, NicQb, 
Niccine) [35-37], different strategies are under exploration to improve anti-nicotine 
immunotherapy that include improved vaccine carriers [25, 38-45]. KLH was found to be a more 
immunogenic carrier than recombinant Pseudomonas Exoprotein A (rEPA) used in NicVAX for 
nicotine vaccine development [46]. Flagellin (FliC) was also explored as both vaccine carriers 
and adjuvants for nicotine vaccine development [47]. FliC-based nicotine vaccine was found to 
induce anti-nicotine antibodies with superior nicotine binding to Tetanus Toxoid (TT)-based 
nicotine vaccine [47]. Here, we first compared relative immunogenicity of KLH to FljB and HBc 
VLPs for nicotine vaccine development. As shown in Suppl. Fig.6A, KLH-Nic elicited ~2 times 
higher anti-nicotine antibody (NicAb) titer than FljB-Nic. In another study, we compared relative 
immunogenicity of KLH-Nic and HBc-Nic and found KLH-Nic elicited ~5 times higher NicAb 
titer than HBc-Nic (Suppl. Fig.6B). These studies indicated KLH was more immunogenic than 
FljB and HBc VLPs for nicotine vaccine development. 
 
Fig.10 High immunogenicity of FH VLPs for nicotine vaccine development 
BALB/c mice were intradermally immunized with KLH-Nic, FH-Nic, or FH-Nic in the presence 
of CpG, Alum, or CpG/Alum adjuvant for total 3 times with a 3-week interval. Serum NicAb 
titer was measured 3 weeks after the last immunization. Mice were then intravenously challenged 
with 0.03 mg/kg nicotine within one week after the last blood collection to measure serum 
NicAb titer. Five minutes later, brain and serum samples were isolated for quantification of 
tissue nicotine levels. A-D. Total IgG titer was shown in A and subtype IgG1 and IgG2a 
antibody titer was shown in B & C, respectively. Ratio of IgG2a to IgG1 antibody titer was 
shown in D. E-F. Brain (E) and serum nicotine levels (F) of different groups. G-I. 
Data of all groups were pooled for linear correlation analysis between NicAb titer and brain 
nicotine levels (G), brain and serum nicotine levels (H), and NicAb titer and serum nicotine 
levels (I). n=6-8 per group. One-way ANOVA with Tukey's Multiple Comparison Test was used 
to compare differences between groups in B and D. One-way ANOVA with Newman-Keuls 
Multiple Comparison Test was used to compare differences between groups in A and C. One-
way ANOVA with Tukey's Multiple Comparison Test was used to compare differences between 
groups in E. One-way ANOVA with Newman-Keuls Multiple Comparison Test was used to 
compare differences between groups in F. *: p<0.05; **: p<0.01; ***: p<0.001. 
 
Next, we compared relative immunogenicity of FH-Nic to KLH-Nic. Due to the synergy 
between two of the three adjuvants (FljB, CpG, and Alum) [48-50], we also evaluated whether 
incorporation of CpG, Alum, or combinatorial CpG/Alum adjuvant could increase 
immunogenicity of FH-Nic. As shown in Fig.10A, FH-Nic elicited more than 4 times higher 
NicAb titer than KLH-Nic. Incorporation of CpG or Alum adjuvant further increased NicAb titer 
by 2.3 and 3.8 times, respectively, while incorporation of CpG/Alum adjuvant failed to further 
increase NicAb titer as compared to incorporation of either adjuvant alone (Fig.10A). Antibody 
isotype analysis found FH-Nic mainly increased anti-nicotine IgG2a but not IgG1 antibody titer 
as compared to KLH-Nic (Fig.10B-C). Incorporation of Th1 adjuvant CpG and Th2 adjuvant 
Alum increased anti-nicotine IgG2a and IgG1 titer, respectively (Fig.10B-C). In line with these 
data, anti-nicotine IgG2a/IgG1 ratio was increased after incorporation of CpG adjuvant and 
reduced after incorporation of Alum adjuvant (Fig.10D). Besides antibody titer, we also 
evaluated antibody avidity index due to its importance in sequestration of nicotine in the 
peripheral tissue. As shown in Suppl. Fig.7, similar antibody avidity index was observed 
between KLH-Nic and FH-Nic groups. Incorporation of Alum or CpG adjuvant into FH-Nic 
vaccination increased antibody avidity to a statistically non-significant level. Interestingly, 
incorporation of combinatorial CpG/Alum adjuvant failed to increase antibody avidity as 
compared to FH-Nic vaccination alone (Suppl. Fig.7). 
 
Mice were further challenged with intravenous nicotine and brain and blood were collected 5 
minutes later to quantify tissue nicotine levels. As compared to brain nicotine levels of non-
immunized mice, KLH-Nic immunization reduced brain nicotine levels by 27% and FH-Nic 
immunization reduced brain nicotine levels by 63% (Fig.10E). Incorporation of Alum or CpG 
adjuvant into FH-Nic immunization reduced brain nicotine levels by 74% and 69%, respectively 
(Fig.10E). Incorporation of CpG/Alum adjuvant into FH-immunization reduced brain nicotine 
levels by 70%, similar to incorporation of CpG adjuvant alone (Fig.10E). Serum nicotine levels 
showed an opposite trend to brain nicotine levels with relatively big variations within groups 
(Fig.10F), in line with other report [51]. Data of all groups were pooled for linear correlation 
analysis. A negative correlation was identified between serum NicAb titer and brain nicotine 
levels (Fig.10G) and between brain and serum nicotine levels (Fig.10H), while a positive 
correlation was found between serum NicAb titer and serum nicotine levels (Fig.10I). The 
negative correlation between serum NicAb titer and brain nicotine levels supports the generation 
of high NicAb titer to block nicotine entry into the brain. Lastly, we explored local and systemic 
safety of ID FH-Nic immunization. As shown in Suppl. Fig.8A, ID FH-Nic induced minimal 
local reactions as supported by the lack of visible changes of FH-Nic-injected skin. ID FH-Nic 
also failed to induce significant systemic reactions as supported by the baseline levels of serum 
IL-6 at 6 and 24 hours after immunization (Suppl. Fig.8B). 
  
Discussion 
This study explored high-density display of flagellin on HBc VLP surface to improve its 
immunogenicity and safety as vaccine carriers. High-density FljB-displayed HBc VLPs or FH 
VLPs were prepared by insertion of full-length FljB into c/e1 loop of HBc followed by E. Coli 
expression and self-assembly. Due to the small size of HBc VLPs, insertion of full-length 
proteins poses a significant risk to interfere with self-assembly of HBc into VLPs. To our 
knowledge, only two full-length proteins (GFP and OspC) less than 250 aa were successfully 
displayed on HBc VLP surface upon c/e1 loop insertion [20, 21]. This study may be the first to 
describe full-length protein of more than 500 aa could be inserted into c/e1 loop of HBc for 
successful display on HBc VLP surface. Close juxtaposition of N- and C-termini of FljB is 
expected to be crucial for the successful display of FljB on HBc VLP surface. The elongated 
D0/D1 domain of FljB may also be important considering the unique structure poses little steric 
hindrance to self-assembly of FH VLPs. Flagellin has been also chemically conjugated to HBc 
VLPs [52, 53]. In those studies, only a small fraction of HBc molecules were conjugated with 
flagellin [52, 53]. Low-density display of flagellin on HBc VLP surface was found not to 
significantly impact its TLR5 activation ability [53]. Besides HBc VLPs, flagellin was also 
displayed on influenza Matrix 1 (M1) VLP surface by co-expression of membrane-anchored 
flagellin and M1 in insect cells [54, 55]. The content of flagellin in M1 VLPs was found to be 
about 1.3% or 8% of total protein [54, 55]. Low-density display of flagellin on M1 VLPs showed 
comparable TLR5 activation ability to free flagellin [54]. Different from these strategies that 
resulted in low-density display of flagellin on VLP surface, self-assembly of FljB-HBc fusion 
protein led to high-density display of FljB onto HBc VLP surface with ~80% flagellin content. 
High-density display of FljB on HBc VLP surface also showed at least 100-fold reduced TLR5 
activation ability as compared to FljB (Fig.2A). Besides significantly reduced TLR5 activation 
ability, FH VLPs also lost most of its NLRC4 inflammasome and Caspase 1 activation ability 
(Fig.2B). D0/D1 domains of FljB, crucial for TLR5 and NLRC4 inflammasome activation, were 
likely buried in interior of FH VLPs without access to TLR5 or NLRC4 inflammasome. In 
support, self-assembly of flagellin into flagella filaments also lost most of the TLR5 activation 
ability due to the embedding of D0/D1 domain of flagellin in interior of flagella filaments [4]. 
Yet, our study cannot exclude the possibility that partially impaired folding of D0/D1 domains of 
FljB also contributed to the significant reduction of TLR5 and NLRC4 inflammasome activation 
ability of FH VLPs. Despite significant reduction of TLR5 activation ability, FH VLPs showed 
similar adjuvant effects to boost co-administered OVA immunization to FljB (Fig.2C-D). This 
result indicated adjuvant effects of flagellin could be maintained even with a significant loss of 
TLR5 activation ability, in line with previous report [11]. Also, FH VLPs induced more than 2-
fold anti-FljB antibody titer than FljB, indicating improved immunogenicity (Fig.7A).  
 
Interestingly, FH VLPs mainly induced anti-FljB IgG2c antibody titer, while FljB mainly 
induced anti-FljB IgG1 antibody titer (Fig.7B-C). Induction of Th1-biased IgG2a antibody 
responses was also reported by influenza M1 VLP-displayed flagellin at relatively low densities 
[54, 55]. These data indicate induction of strong anti-FljB IgG2 antibody responses may be the 
common feature of VLP-displayed flagellin regardless of high- or low-density display. Induction 
of strong IgG2 antibody responses was in line with our observation that FH VLPs but not FljB 
induced BMDCs to secret high levels of IL-12, which is a key cytokine to induce Th1-skewing 
immune responses [34]. Significant reduction of IgG2c antibody titer in MyD88 KO mice 
(Fig.7C) indicated crucial roles of MyD88 in FH VLP-induced IgG2c antibody production. Yet, 
significant IgG2c antibody titer was still induced in the absence of MyD88 (Fig.7C), indicating 
FH VLPs also activated other signaling pathways to mediate IgG2c antibody production. FH 
VLPs failed to induce significant anti-HBc antibody production due to the embedding of HBc in 
interior of FH VLPs (Fig.7D). The high immunogenicity of FH VLPs could be explained by its 
increased uptake by APCs and induction of stronger DC maturation than FljB (Fig.4-6, Suppl. 
Fig.4). The increased uptake of FH VLPs may simply reflect more efficient uptake of particulate 
antigens by phagocytosis than soluble antigen uptake by non-receptor-mediated endocytosis 
(macropinocytosis) [56]. Increased uptake of FH VLPs may also be mediated by cell surface 
receptors. Although murine BMDCs don’t express TLR5 [31], we cannot exclude the possibility 
of other cell surface receptors, such as glycolipids/gangliosides (e.g., asialo-GM1, GM1, GD1a) 
and lipid rafts [57], that more efficiently bind high-density displayed FljB than soluble FljB, 
leading to more efficient uptake of FH VLPs than FljB. Our studies found FH VLPs specifically 
increased CD40 expression on DC surface with no significant effects on CD80 and CD86 
expression (Fig.5-6). All the other stimuli, like FljB, FLA-ST, and HBc VLPs, showed no 
significant effects on CD40, CD80, or CD86 expression on DC surface (Fig.5-6).  
 
Using nicotine vaccine as a model, we compared relative immunogenicity of FH VLPs to FljB, 
HBc VLPs, and widely used KLH for nicotine vaccine development. FH VLPs were found to be 
a more immunogenic carrier than the widely used KLH and KLH was more immunogenic than 
FljB and HBc VLPs for nicotine vaccine development (Fig.10A, Suppl. Fig.6). FH-Nic 
immunization induced ~4 times higher NicAb titer and more significant inhibited nicotine entry 
into the brain than KLH-Nic immunization (Fig.10A & E). Few studies directly compared 
relative immunogenicity of FljB to KLH for vaccine development. Lockner et al. found FliC-
based cocaine vaccine elicited comparable anti-cocaine hapten antibody titer to KLH-based 
cocaine vaccine in the presence of Alum adjuvant [48]. In consideration of potential synergy 
between Alum and FliC, immunogenicity of FliC for cocaine vaccine development might be 
weaker than KLH, consistent with the observation in our nicotine vaccine development studies. 
We found incorporation of Alum or CpG adjuvant into FH-Nic immunization could further 
increase NicAb production and reduce nicotine entry into the brain after nicotine challenge 
(Fig.10A & E). Interestingly, incorporation of CpG/Alum adjuvant failed to further increase 
NicAb production and yet induced more Th1-biased immune responses (Fig.10A & D). These 
results indicated no advantages to incorporate both Alum and CpG adjuvants to boost FH-Nic-
induced antibody responses. 
 
Besides high immunogenicity, FH VLPs showed a good system safety. FH VLPs induced more 
transient systemic IL-6 release than FljB in C57BL/6 mice and FH VLPs failed to significantly 
increase serum IL-6 levels in BALB/c mice (Fig.8A-D). Furthermore, FH VLPs failed to 
increase rectal temperature of mice even after repeated administrations at relatively high doses, 
while soluble FljB at an equivalent dose consistently and significantly increased rectal 
temperature of mice (Fig.8E-G). No significant microscopic organ damage or body weight 
change relative to control group was observed following FH VLP immunization (Fig.9). These 
results indicated FH VLPs had improved systemic safety than FljB.  
 
VLPs are self-assembled nanostructures, mimicking the size and shape of infectious viruses, and 
can be used as vaccines alone. VLP-based hepatitis b vaccine and human papillomavirus vaccine 
have been approved for human use [22]. VLPs are also highly attractive vaccine carriers and can 
be engineered to express foreign antigens to elicit potent immune responses [58]. High-density 
display of FljB on HBc VLP surface generates a new VLP delivery platform (FH VLPs) with 
good immunogenicity and safety for vaccine development. This study found FH VLPs to be a 
highly immunogenic carrier for conjugate vaccine development. Besides conjugate vaccines, 
antigenic epitopes can be inserted into the flexible D3 domain of FljB for high-density display of 
FH VLP surface. Even full-length proteins may be inserted into D3 domain or replace D3 
domain for high-density display on FH VLP surface. Thus, FH VLPs may provide a more 
versatile delivery platform than HBc VLPs considering c/e1 loop of HBc only allows insertion of 
relatively short antigenic epitopes and D3 domain of flagellin allows insertion of foreign 
antigens with less restriction on lengths and 3D structures. FljB-HBc fusion proteins can be 
conveniently expressed in E. Coli in large scale and refolded in vitro to form VLPs. The superior 
immunogenicity, good safety, and large-scale production support further development of FH 
VLPs to use as vaccine carriers. 
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